BPC-157 in Laboratory Research: Angiogenesis, FAK–Paxillin Signaling, and Evidence Boundaries

Introduction to BPC-157 Research Peptides

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide studied in laboratory and animal models of tissue injury, including tendon, ligament, muscle, and gastrointestinal models [1, 12]. It has one of the largest preclinical literatures of any research peptide. It also has one of the widest gaps between preclinical findings and human evidence.

That gap is the central fact for anyone reading the BPC-157 literature. Published reviews describe consistent effects across animal models and several proposed signaling mechanisms. The same reviews describe very limited human data, an evidence base concentrated in one research group, and incomplete pharmacokinetic characterization [1, 11, 12, 14].

This article reviews BPC-157’s molecular profile, its proposed mechanisms, the models in which it has been studied, and the boundaries of the current evidence. It is for laboratory research and education only. It is not medical, diagnostic, therapeutic, dosing, administration, or human-use guidance.

Molecular profile

BPC-157 is a pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) and a molecular weight of about 1419.55 Da [1]. It was first described in 1993 as a partial sequence of a larger protein isolated from human gastric juice. The sequence shows no homology with known intestinal peptides [1].

Two properties are frequently highlighted in the literature:

• Reported stability. BPC-157 is often described as stable in gastric juice, which is why much of the animal literature includes oral as well as parenteral administration routes [2].
• No identified receptor. A specific receptor for BPC-157 has not been conclusively identified. Its proposed effects are described through downstream signaling changes rather than a defined primary target [1].

The absence of an identified receptor matters for experimental design. Without a known target, it is harder to confirm on-target activity, design selective controls, or explain why a single peptide is reported to act across so many tissues.

Formal absorption, distribution, metabolism, and excretion (ADME) data are limited. A 2022 study characterized BPC-157 pharmacokinetics, distribution, metabolism, and excretion in rats and dogs [10]. Comparable human pharmacokinetic data remain sparse [12, 14].

Proposed mechanisms

Because no primary receptor has been confirmed, the BPC-157 literature describes its activity through effects on several signaling pathways. Most of these findings come from cell culture and rodent tissue models.

• FAK–paxillin signaling and cell migration. In rat Achilles tendon explants and cultured tendon fibroblasts, BPC-157 was associated with increased fibroblast outgrowth, survival under oxidative stress, and migration, along with increased phosphorylation of FAK and paxillin [3]. FAK and paxillin are focal adhesion proteins involved in how cells attach to and move across the extracellular matrix.
• Growth hormone receptor expression. A follow-up study from the same laboratory reported increased growth hormone receptor expression in cultured tendon fibroblasts exposed to BPC-157 [4].
• VEGFR2 and angiogenesis. In endothelial cell and rat models, BPC-157 was associated with increased VEGFR2 expression and activation, with downstream effects on endothelial tube formation and blood-flow recovery [5].
• Nitric oxide signaling. A 2020 study reported effects on vasomotor tone and activation of a Src–caveolin-1–endothelial nitric oxide synthase (eNOS) pathway [6]. Interaction with the nitric oxide system is a recurring theme in reviews from the group that first described the peptide [2].

Reviews summarize these findings as pleiotropic activity across angiogenic, migratory, and anti-inflammatory pathways [11, 12]. A pleiotropic profile is consistent with a peptide that acts on a broadly expressed upstream target. It is also consistent with experimental heterogeneity. The current literature does not distinguish between these explanations.

Research models studied

BPC-157 has been examined across a wide range of injury models. The musculoskeletal studies are the most frequently cited, and nearly all of them use rats.

Model	System	Reported finding	Source
Transected Achilles tendon	Rat, in vivo; tendocytes in vitro	Improved healing measures; tendocyte growth in culture	[7]
Tendon explants and fibroblasts	Rat tissue; cell culture	Increased outgrowth, survival, migration; FAK–paxillin activation	[3]
Ligament injury	Rat, in vivo	Improved ligament healing measures	[8]
Transected quadriceps muscle	Rat, in vivo	Improved muscle healing measures	[9]
Endothelial cells; ischemia model	Cell culture; rat, in vivo	VEGFR2 upregulation, tube formation, blood-flow recovery	[5]
Gastrointestinal lesion models	Rat, in vivo	Reduced lesions across several injury models	[2]

The systematic review by Vasireddi and colleagues screened the orthopaedic sports medicine literature from 1993 to 2024. It concluded that the included studies were level IV and level V evidence, and that BPC-157 shows promise in preclinical musculoskeletal models [11]. That conclusion describes a direction of effect in animals, not demonstrated outcomes in people.

Who produced the evidence

The source of a literature matters as much as its size. BPC-157 was first described by a research group at the University of Zagreb led by Predrag Sikiric, and that group remains the dominant contributor. In a 2025 exchange in Pharmaceuticals, Józwiak and colleagues reported that more than 80% of the PubMed articles mentioning BPC 157 in their search listed Sikiric as an author [14]. Several of the tendon, ligament, and muscle studies in the table above come from that group [7, 8, 9].

Independent work exists. The FAK–paxillin, growth hormone receptor, VEGFR2, and eNOS studies came from researchers in Taiwan [3, 4, 5, 6], and the rat and dog ADME study from researchers in China [10]. But independent replication of the core musculoskeletal findings remains limited.

The same exchange illustrates an open scientific disagreement. Józwiak and colleagues raised questions about long-term safety, including whether pro-angiogenic signaling could have consequences in tumor biology, and noted the lack of basic pharmacodynamic and pharmacokinetic profiling [1, 14]. Sikiric and colleagues responded that these concerns misread the angiogenesis and nitric oxide literature [13]. Neither position has been settled by independent data.

Concentration in one group does not make findings wrong. It does mean that replication by independent laboratories, using independently sourced and characterized material, is the most important missing piece of the evidence base.

Human data and regulatory status

Human evidence for BPC-157 is minimal. A 2025 narrative review identified only three pilot human studies: a retrospective report on intra-articular use for knee pain, a pilot study in interstitial cystitis, and a small intravenous safety and pharmacokinetics study [12]. All three were small pilot studies, and the review noted that rigorous, large-scale trials are lacking. The review concluded that BPC-157 should be considered investigational [12].

Regulators and anti-doping bodies have addressed BPC-157 directly:

• FDA. BPC-157 is not approved for any use. On its compounding page (current as of April 2026), the FDA lists BPC-157 among bulk drug substances previously placed in category 2 whose nominations were withdrawn. The agency states that compounded BPC-157 may pose immunogenicity risks for certain routes, may involve peptide-related impurities and characterization complexities, and that it lacks sufficient information to know whether the drug would cause harm in humans [15].
• Anti-doping. BPC-157 has been on the World Anti-Doping Agency Prohibited List since 2022, under the category of non-approved substances [16].

The FDA’s concerns about impurities and characterization are worth noting for researchers, because they apply to any material, not just compounded products. They reinforce the need for lot-specific identity and purity documentation.

Evidence boundaries: what current data do not establish

The volume of BPC-157 publications can create an impression of certainty that the evidence does not support. Researchers should keep these limits in view.

• Rodent findings are not human findings. The musculoskeletal evidence is almost entirely from rat models [11, 12]. Healing biology, pharmacokinetics, and tissue structure differ substantially between rodents and humans.
• Consistency is not replication. Results that point in the same direction across many studies carry less weight when most of those studies come from one research group [14].
• Proposed mechanisms are not a confirmed mechanism. FAK–paxillin, VEGFR2, growth hormone receptor, and nitric oxide findings are each supported by a small number of studies [3, 4, 5, 6]. No primary receptor has been confirmed, and how these pathways relate to each other is unresolved.
• Pilot studies are not trials. The three human studies were small pilot studies, not randomized controlled trials [12]. They cannot establish efficacy or characterize safety.
• Absence of reported harm is not evidence of safety. The pilot human studies reported no adverse effects, but they were too small and short to characterize safety [12]. Long-term effects, including the open question about pro-angiogenic signaling, have not been studied [1, 14].
• Published findings say nothing about a specific vial. Results describe the material used in those studies. They do not establish the identity, purity, or stability of any other material, which requires lot-specific documentation as described in our guide to evaluating research peptide documentation.
• Regulatory status. BPC-157 is not approved by the FDA for any use, and it is prohibited in sport [15, 16].

Questions researchers can ask

When designing or reviewing work involving BPC-157, researchers can ask:

• Is a cited finding from an independent laboratory, or from the group that first described the peptide? Has it been replicated elsewhere?
• Is the finding from cell culture, a rodent model, or human data?
• What controls separate a specific pathway effect (for example, FAK–paxillin or VEGFR2) from a general effect on cell viability or proliferation?
• Without a confirmed receptor, how will on-target activity be demonstrated in the assay system?
• Does the study report the identity, purity, and source of the BPC-157 used?
• Is the material’s identity confirmed for the specific lot, ideally by mass spectrometry, with purity by HPLC and a matching Certificate of Analysis?
• Are storage, reconstitution, and freeze-thaw history recorded, so that a negative or unexpected result can be traced back to the material?

Related research

• How to Evaluate Research Peptide Documentation: COAs, Identity Testing, and Batch Traceability
• MOTS-c Research Overview: Mitochondrial-Derived Signaling, Cellular Stress, and Evidence Boundaries
• Tirzepatide in Laboratory Research: Receptor Biology, Molecular Design, and Evidence Boundaries

Research Use Only notice

This article is provided solely for laboratory research education and scientific information. Any research materials referenced by Genoscience are intended exclusively for qualified laboratory research and are not medicines, diagnostic products, dietary supplements, or treatments. They are not intended for human or veterinary use. This article does not provide instructions for administration, dosing, self-experimentation, or clinical decision-making. Product identity, purity, storage, quality, and compliance statements should be reviewed against the applicable lot documentation and by qualified scientific, legal, and regulatory professionals where appropriate.

Conclusion

BPC-157 is a 15-amino-acid peptide with an extensive preclinical literature describing effects on cell migration, angiogenesis, and tissue repair in rodent models. Proposed mechanisms include FAK–paxillin activation, VEGFR2 upregulation, growth hormone receptor expression, and nitric oxide signaling, though no primary receptor has been confirmed.

The evidence base has clear limits. It is concentrated in one research group, independent replication is limited, human data consist of three small pilot studies, and pharmacokinetic and long-term safety characterization is incomplete. Researchers will get the most from this literature by tracking where each finding comes from, which model produced it, and whether it has been independently reproduced, and by documenting their own material at the lot level.

References

1. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. “Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review.” Pharmaceuticals 18 (2025): 185. https://doi.org/10.3390/ph18020185
2. Sikiric P, Seiwerth S, Rucman R, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Current Pharmaceutical Design 17 (2011): 1612–1632. https://doi.org/10.2174/138161211796196954
3. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of Applied Physiology 110 (2011): 774–780. https://doi.org/10.1152/japplphysiol.00945.2010
4. Chang CH, Tsai WC, Hsu YH, Pang JHS. “Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.” Molecules 19 (2014): 19066–19077. https://doi.org/10.3390/molecules191119066
5. Hsieh MJ, Liu HT, Wang CN, et al. “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.” Journal of Molecular Medicine 95 (2017): 323–333. https://doi.org/10.1007/s00109-016-1488-y
6. Hsieh MJ, Lee CH, Chueh HY, et al. “Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway.” Scientific Reports 10 (2020): 17078. https://doi.org/10.1038/s41598-020-74022-y
7. Staresinic M, Sebecic B, Patrlj L, et al. “Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.” Journal of Orthopaedic Research 21 (2003): 976–983. https://doi.org/10.1016/S0736-0266(03)00110-4
8. Cerovecki T, Bojanic I, Brcic L, et al. “Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.” Journal of Orthopaedic Research 28 (2010): 1155–1161. https://doi.org/10.1002/jor.21107
9. Staresinic M, Petrovic I, Novinscak T, et al. “Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157.” Journal of Orthopaedic Research 24 (2006): 1109–1117. https://doi.org/10.1002/jor.20089
10. He L, Feng D, Guo H, et al. “Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.” Frontiers in Pharmacology 13 (2022): 1026182. https://doi.org/10.3389/fphar.2022.1026182
11. Vasireddi N, Hahamyan H, Salata MJ, et al. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” HSS Journal (2025). https://doi.org/10.1177/15563316251355551
12. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. “Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.” Current Reviews in Musculoskeletal Medicine 18 (2025): 611–619. https://doi.org/10.1007/s12178-025-09990-7
13. Sikiric P, et al. “BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions.” Comment. Pharmaceuticals 18 (2025): 1450. https://doi.org/10.3390/ph18101450
14. Józwiak M, et al. Reply to Sikiric et al. Pharmaceuticals 18 (2025): 1451. https://doi.org/10.3390/ph18101451
15. U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.” Content current as of April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
16. U.S. Anti-Doping Agency. “Explanation of Key Changes on 2022 WADA Prohibited List.” https://www.usada.org/athlete-advisory/key-changes-2022-prohibited-list/